Refine
Has Fulltext
- yes (72)
Is part of the Bibliography
- yes (72)
Year of publication
Document Type
- Journal article (59)
- Conference Proceeding (7)
- Preprint (6)
Language
- English (72) (remove)
Keywords
- PET (21)
- Positronen-Emissions-Tomografie (20)
- positron emission tomography (15)
- theranostics (9)
- neuroendocrine tumor (8)
- prostate cancer (7)
- SPECT (6)
- 18F-FDG (5)
- PET/CT (5)
- PRRT (5)
- PSMA (5)
- RADS (5)
- SSTR (5)
- CXCR4 (4)
- inflammation (4)
- molecular imaging (4)
- norepinephrine transporter (4)
- prostate-specific membrane antigen (4)
- radioligand therapy (4)
- sympathetic nervous system (4)
- 18F-DCFPyL (3)
- 18F-LMI1195 (3)
- DaTscan (3)
- Prostate Cancer (3)
- ageing (3)
- peptide receptor radionuclide therapy (3)
- somatostatin receptor (3)
- vandetanib (3)
- 11C-HED (2)
- 18F-FDS (2)
- Ioflupane (2)
- MIBG (2)
- MRI (2)
- Myokarditis (2)
- PSMA-PET (2)
- PSMA-RADS (2)
- Parkinson (2)
- Parkinson Disease (2)
- Parkinson-Krankheit (2)
- Positron Emission Tomography (2)
- SSTR-RADS (2)
- Stammzelle (2)
- TKI (2)
- Virchow Node (2)
- [177Lu]-DOTATATE/-DOTATOC (2)
- [68Ga] (2)
- antidepressant (2)
- cardiomyocytes (2)
- chemokine receptor (2)
- diabetes (2)
- fatty acid (2)
- heart (2)
- heart failure (2)
- hiPSC-CM (2)
- induced pluripotent stem cells (2)
- kidney (2)
- machine learning (2)
- medullary thyroid carcinoma (2)
- molecular medicine (2)
- myocardial sympathetic innervation imaging (2)
- myocarditis (2)
- personalized medicine (2)
- personalized treatment (2)
- precision medicine (2)
- prostate-specific membrane antigen (PSMA) (2)
- reporting and data system (2)
- somatostatin receptor (SSTR) (2)
- stem cell therapy (2)
- tracer (2)
- tumor heterogeneity (2)
- tyrosine kinase inhibitor (2)
- 11C-Hydroxyephedrine (1)
- 11C-hydroxyephedrine (1)
- 123I-Ioflupane (1)
- 123I-mIBG (1)
- 123I-metaiodobenzylguanidine (1)
- 177Lu (1)
- 18F-DCFPL (1)
- 18F-flurpiridaz (1)
- 18FFBnTP (1)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-18F-fluoro-D-sorbitol (1)
- 5IA-SPECT (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-DOTATOC (1)
- 99mTc-DTPA (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- AI (1)
- Alzheimer’s disease (1)
- Antidepressants (1)
- C-X-C motif chemokine receptor 4 (1)
- COVID-19 (1)
- CTCAE (1)
- CXCR4-targeting (1)
- Cardiovascular diseases (1)
- DCGAN (1)
- DOTATOC (1)
- DYT1 (1)
- Dystonia (1)
- ECG (1)
- FV45 (1)
- GAN (1)
- GCA (1)
- GI (1)
- Ganglia (1)
- Gastrointestinal (1)
- Glomerular filtration (1)
- HFmrEF (1)
- HMDP hydroxymethylene diphosphonate (1)
- Heart failure (1)
- Herz (1)
- Imaging pitfalls (1)
- Journal of Nuclear Cardiology (1)
- MAG3 (1)
- MDD (1)
- MI-RADS (1)
- MPI (1)
- Magnetresonanztomografie (1)
- Medullärer Schilddrüsenkrebs (1)
- Metaiodobenzylguanidine (1)
- Myocardial-perfusion SPECT (1)
- NEC (1)
- NET (1)
- Neuroendocrine (1)
- Neuroendocrine Tumor (1)
- Nierenfunktionsstörung (1)
- OXPHOS (1)
- Oncology (1)
- P-glycoprotein expression (1)
- PMR (1)
- PROMISE (1)
- PSMA I&T (1)
- PSMA-617 (1)
- PSMA-RADS-3A (1)
- PSMA-RADS-3B (1)
- PSMA-targeted PET (1)
- Pancreas (1)
- Parkinson disease (1)
- Parkinsonism (1)
- Parkinson’s disease (1)
- Pitfall (1)
- Positron-Emission Tomography (1)
- Positronenemissionstomografie (1)
- Prostata (1)
- RLT (1)
- ROS (1)
- Radiofluorine (1)
- Radionuclide Therapy (1)
- Radiotracer (1)
- SARS-CoV-2 (1)
- SPECT Scanner (1)
- SPECT/CT (1)
- SSTR-PET (1)
- SUV (1)
- Simvastatin (1)
- Single-Photon-Emissions-Computertomographie (1)
- Sodium-Glucose Cotransporters (SGLTs) (1)
- Standardisierung (1)
- T-shaped π-π stacking (1)
- T-shaped π–π stacking (1)
- Technetium Tc 99m Sestamibi Rats (1)
- Tracer (1)
- ZDF rats (1)
- [177Lu]/[90Y]PentixaTher (1)
- [18F]FDG PET/CT (1)
- [68Ga]DOTATOC (1)
- [68Ga]PentixaFor (1)
- [68Ga]Pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{177}\)Lu (1)
- \(^{18}\)F (1)
- \(^{18}\)F-FDG (1)
- \(^{18}\)F-fluorodeoxyglucose (1)
- \(^{68}\)Ga (1)
- amyloid-β (Aβ) (1)
- angiotensin II type 1 receptor (1)
- antidepressants (1)
- artificial intelligence (1)
- autonomic nervous system (1)
- benzylguanidine (1)
- biomarkers (1)
- blood flow (1)
- butyrylcholinesterase (1)
- carbamate (1)
- cardiac (1)
- cardiac innervation imaging (1)
- cardiac nerve (1)
- cardiac neurohormonal system (1)
- cardiac sympathetic nerve system (1)
- cardiac sympathetic nervous system (1)
- cardioprotective potential (1)
- cell biology (1)
- cognitive decline (1)
- combination (1)
- computational biology and bioinformatics (1)
- contractility (1)
- coronary artery disease (1)
- depression (1)
- diabetic cardiomyopathy (1)
- dilated cardiomyopathy with ataxia (1)
- dopamine (1)
- dopamine acetylcholine (1)
- editorial (1)
- ejection fraction (1)
- endocrinology (1)
- endoradiotherapy (1)
- enzyme kinetics (1)
- fibroblast activation protein (1)
- fluorine-18 (1)
- genetics (1)
- giant cell arteritis (1)
- glomerular filtration rate (1)
- heart failure with mid-range ejection fraction (1)
- hematotoxicity (1)
- hydroxyephedrine (1)
- interobserver (1)
- interreader (1)
- left-ventricular function (1)
- mIBG (1)
- magnetic resonance imaging (1)
- major depressive disorder (1)
- matched pair (1)
- mechanisms retention (1)
- medium-sized animals (1)
- meningioma (1)
- metabolism (1)
- mitochondria (1)
- molecular biology (1)
- mouse (1)
- moycardial sympathetic innervation (1)
- myocardial perfusion imaging (1)
- nephrology (1)
- nephrotoxicity (1)
- neuroblastoma (1)
- neuroendocrine neoplasia (1)
- neuroendocrine neoplasms (NEN) (1)
- neuroendocrine tumors (NET) (1)
- neurology (1)
- nicotinic receptors (1)
- nonhuman primates (1)
- nuclear cardiology (1)
- ollimator (1)
- organic cation transporter (1)
- pancreas (1)
- papillary thyroid carcinoma (PTC) (1)
- performance (1)
- peripheral injury (1)
- phaeochromocytoma (1)
- phenethylguanidine (1)
- polymyalgia rheumatica (1)
- post-reconstruction filtering (1)
- quality (1)
- quantification (1)
- radioiodine (1)
- radiotracer (1)
- radiotracer kinetics (1)
- radiotracers (1)
- rats (1)
- renal (1)
- renal failure (1)
- renal function (1)
- renal imaging (1)
- renal scintigraphy (1)
- renin-angiotensin system (1)
- reporting and data systems (1)
- scanner (1)
- second hit (1)
- selpercatinib (1)
- sepsis (1)
- sigma-1 receptor-directed molecular imaging (1)
- single photon emission computed tomography: sympathetic nerve (1)
- skeletal (1)
- small animal SPECT (1)
- small-animal imaging (1)
- solid tumors (1)
- split renal function (1)
- standardization (1)
- standardized reporting (1)
- statin (1)
- stem cells (1)
- stem-cell research (1)
- storage vesicle turnover (1)
- stroke (1)
- structure–activity relationships (1)
- sympathetic nerve (1)
- thyroid carcinoma (TC) (1)
- unilateral ureteral obstruction (1)
- urology (1)
- valsartan (1)
- vasculature (1)
- vasculitis (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (72) (remove)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (17)
- Johns Hopkins University School of Medicine (5)
- Johns Hopkins School of Medicine, Baltimore, MD, U.S. (3)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (2)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (2)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (2)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (2)
- Department of Nuclear Medicine, Kanazawa University (1)
- Hospital Augsburg, Augsburg, Germany (1)
- Johns Hopkins School of Medicine, Baltimore, MD, USA (1)
Highlights
• Loss of DNAJC19's DnaJ domain disrupts cardiac mitochondrial structure, leading to abnormal cristae formation in iPSC-CMs.
• Impaired mitochondrial structures lead to an increased mitochondrial respiration, ROS and an elevated membrane potential.
• Mutant iPSC-CMs show sarcomere dysfunction and a trend to more arrhythmias, resembling DCMA-associated cardiomyopathy.
Background
Dilated cardiomyopathy with ataxia (DCMA) is an autosomal recessive disorder arising from truncating mutations in DNAJC19, which encodes an inner mitochondrial membrane protein. Clinical features include an early onset, often life-threatening, cardiomyopathy associated with other metabolic features. Here, we aim to understand the metabolic and pathophysiological mechanisms of mutant DNAJC19 for the development of cardiomyopathy.
Methods
We generated induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) of two affected siblings with DCMA and a gene-edited truncation variant (tv) of DNAJC19 which all lack the conserved DnaJ interaction domain. The mutant iPSC-CMs and their respective control cells were subjected to various analyses, including assessments of morphology, metabolic function, and physiological consequences such as Ca\(^{2+}\) kinetics, contractility, and arrhythmic potential. Validation of respiration analysis was done in a gene-edited HeLa cell line (DNAJC19tv\(_{HeLa}\)).
Results
Structural analyses revealed mitochondrial fragmentation and abnormal cristae formation associated with an overall reduced mitochondrial protein expression in mutant iPSC-CMs. Morphological alterations were associated with higher oxygen consumption rates (OCRs) in all three mutant iPSC-CMs, indicating higher electron transport chain activity to meet cellular ATP demands. Additionally, increased extracellular acidification rates suggested an increase in overall metabolic flux, while radioactive tracer uptake studies revealed decreased fatty acid uptake and utilization of glucose. Mutant iPSC-CMs also showed increased reactive oxygen species (ROS) and an elevated mitochondrial membrane potential. Increased mitochondrial respiration with pyruvate and malate as substrates was observed in mutant DNAJC19tv HeLa cells in addition to an upregulation of respiratory chain complexes, while cellular ATP-levels remain the same. Moreover, mitochondrial alterations were associated with increased beating frequencies, elevated diastolic Ca\(^{2+}\) concentrations, reduced sarcomere shortening and an increased beat-to-beat rate variability in mutant cell lines in response to β-adrenergic stimulation.
Conclusions
Loss of the DnaJ domain disturbs cardiac mitochondrial structure with abnormal cristae formation and leads to mitochondrial dysfunction, suggesting that DNAJC19 plays an essential role in mitochondrial morphogenesis and biogenesis. Moreover, increased mitochondrial respiration, altered substrate utilization, increased ROS production and abnormal Ca\(^{2+}\) kinetics provide insights into the pathogenesis of DCMA-related cardiomyopathy.
Purpose: A new PET radiotracer \(^{18}\)F-AF78 showing great potential for clinical application has been reported recently. It belongs to a new generation of phenethylguanidine-based norepinephrine transporter (NET)-targeting radiotracers. Although many efforts have been made to develop NET inhibitors as antidepressants, systemic investigations of the structure–activity relationships (SARs) of NET-targeting radiotracers have rarely been performed. Methods: Without changing the phenethylguanidine pharmacophore and 3-fluoropropyl moiety that is crucial for easy labeling, six new analogs of \(^{18}\)F-AF78 with different meta-substituents on the benzene-ring were synthesized and evaluated in a competitive cellular uptake assay and in in vivo animal experiments in rats. Computational modeling of these tracers was established to quantitatively rationalize the interaction between the radiotracers and NET. Results: Using non-radiolabeled reference compounds, a competitive cellular uptake assay showed a decrease in NET-transporting affinity from meta-fluorine to iodine (0.42 and 6.51 µM, respectively), with meta-OH being the least active (22.67 µM). Furthermore, in vivo animal studies with radioisotopes showed that heart-to-blood ratios agreed with the cellular experiments, with AF78(F) exhibiting the highest cardiac uptake. This result correlates positively with the electronegativity rather than the atomic radius of the meta-substituent. Computational modeling studies revealed a crucial influence of halogen substituents on the radiotracer–NET interaction, whereby a T-shaped π–π stacking interaction between the benzene-ring of the tracer and the amino acid residues surrounding the NET binding site made major contributions to the different affinities, in accordance with the pharmacological data. Conclusion: The SARs were characterized by in vitro and in vivo evaluation, and computational modeling quantitatively rationalized the interaction between radiotracers and the NET binding site. These findings pave the way for further evaluation in different species and underline the potential of AF78(F) for clinical application, e.g., cardiac innervation imaging or molecular imaging of neuroendocrine tumors.
Background. Mediating glucose absorption in the small intestine and renal clearance, sodium glucose cotransporters (SGLTs) have emerged as an attractive therapeutic target in diabetic patients. A substantial fraction of patients, however, only achieve inadequate glycemic control. Thus, we aimed to assess the potential of the SGLT-targeting PET radiotracer alpha-methyl-4-deoxy-4-[\(^{18}\)F]fluoro-D-glucopyranoside ([\(^{18}\)F]Me4FDG) as a noninvasive intestinal and renal biomarker of SGLT-mediated glucose transport. Methods. We investigated healthy rats using a dedicated small animal PET system. Dynamic imaging was conducted after administration of the reference radiotracer 2-deoxy-2-[\(^{18}\)F]fluoro-D-glucose ([\(^{18}\)F]FDG), or the SGLT-targeting agent, [\(^{18}\)F]Me4FDG either directly into the digestive tract (for assessing intestinal absorption) or via the tail vein (for evaluating kidney excretion). To confirm the specificity of [18F]Me4FDG and responsiveness to treatment, a subset of animals was also pretreated with the SGLT inhibitor phlorizin. In this regard, an intraintestinal route of administration was used to assess tracer absorption in the digestive tract, while for renal assessment, phlorizin was injected intravenously (IV). Results. Serving as reference, intestinal administration of [\(^{18}\)F]FDG led to slow absorption with retention of % of administered radioactivity at 15 min. [\(^{18}\)F]Me4FDG, however, was rapidly absorbed into the blood and cleared from the intestine within 15 min, leading to markedly lower tracer retention of % (). Intraintestinal phlorizin led to marked increase of [\(^{18}\)F]Me4FDG uptake (15 min, %; vs. untreated controls), supporting the notion that this PET agent can measure adequate SGLT inhibition in the digestive tract. In the kidneys, radiotracer was also sensitive to SGLT inhibition. After IV injection, [\(^{18}\)F]Me4FDG reabsorption in the renal cortex was significantly suppressed by phlorizin when compared to untreated animals (%ID/g at 60 min, vs. untreated controls, ; ). Conclusion. As a noninvasive read-out of the concurrent SGLT expression in both the digestive tract and the renal cortex, [\(^{18}\)F]Me4FDG PET may serve as a surrogate marker for treatment response to SGLT inhibition. As such, [\(^{18}\)F]Me4FDG may enable improvement in glycemic control in diabetes by PET-based monitoring strategies.
(1) Background: We aimed to quantitatively investigate [\(^{68}\)Ga]Ga-FAPI-04 uptake in normal organs and to assess a relationship with the extent of FAPI-avid tumor burden. (2) Methods: In this single-center retrospective analysis, thirty-four patients with solid cancers underwent a total of 40 [\(^{68}\)Ga]Ga-FAPI-04 PET/CT scans. Mean standardized uptake values (SUV\(_{mean}\)) for normal organs were established by placing volumes of interest (VOIs) in the heart, liver, spleen, pancreas, kidneys, and bone marrow. Total tumor burden was determined by manual segmentation of tumor lesions with increased uptake. For tumor burden, quantitative assessment included maximum SUV (SUV\(_{max}\)), tumor volume (TV), and fractional tumor activity (FTA = TV × SUV\(_{mean}\)). Associations between uptake in normal organs and tumor burden were investigated by applying Spearman's rank correlation coefficient. (3) Results: Median SUV\(_{mean}\) values were 2.15 in the pancreas (range, 1.05–9.91), 1.42 in the right (range, 0.57–3.06) and 1.41 in the left kidney (range, 0.73–2.97), 1.2 in the heart (range, 0.46–2.59), 0.86 in the spleen (range, 0.55–1.58), 0.65 in the liver (range, 0.31–2.11), and 0.57 in the bone marrow (range, 0.26–0.94). We observed a trend towards significance for uptake in the myocardium and tumor-derived SUV\(_{max}\) (ρ = 0.29, p = 0.07) and TV (ρ = −0.30, p = 0.06). No significant correlation was achieved for any of the other organs: SUV\(_{max}\) (ρ ≤ 0.1, p ≥ 0.42), TV (ρ ≤ 0.11, p ≥ 0.43), and FTA (ρ ≤ 0.14, p ≥ 0.38). In a sub-analysis exclusively investigating patients with high tumor burden, significant correlations of myocardial uptake with tumor SUV\(_{max}\) (ρ = 0.44; p = 0.03) and tumor-derived FTA with liver uptake (ρ = 0.47; p = 0.02) were recorded. (4) Conclusions: In this proof-of-concept study, quantification of [\(^{68}\)Ga]Ga-FAPI-04 PET showed no significant correlation between normal organs and tumor burden, except for a trend in the myocardium. Those preliminary findings may trigger future studies to determine possible implications for treatment with radioactive FAP-targeted drugs, as higher tumor load or uptake may not lead to decreased doses in the majority of normal organs.
Background
CXCR4-directed positron emission tomography/computed tomography (PET/CT) has been used as a diagnostic tool in patients with solid tumors. We aimed to determine a potential correlation between tumor burden and radiotracer accumulation in normal organs.
Methods
Ninety patients with histologically proven solid cancers underwent CXCR4-targeted [\(^{68}\)Ga]Ga-PentixaFor PET/CT. Volumes of interest (VOIs) were placed in normal organs (heart, liver, spleen, bone marrow, and kidneys) and tumor lesions. Mean standardized uptake values (SUV\(_{mean}\)) for normal organs were determined. For CXCR4-positive tumor burden, maximum SUV (SUV\(_{max}\)), tumor volume (TV), and fractional tumor activity (FTA, defined as SUV\(_{mean}\) x TV), were calculated. We used a Spearman's rank correlation coefficient (ρ) to derive correlative indices between normal organ uptake and tumor burden.
Results
Median SUV\(_{mean}\) in unaffected organs was 5.2 for the spleen (range, 2.44 – 10.55), 3.27 for the kidneys (range, 1.52 – 17.4), followed by bone marrow (1.76, range, 0.84 – 3.98), heart (1.66, range, 0.88 – 2.89), and liver (1.28, range, 0.73 – 2.45). No significant correlation between SUV\(_{max}\) in tumor lesions (ρ ≤ 0.189, P ≥ 0.07), TV (ρ ≥ -0.204, P ≥ 0.06) or FTA (ρ ≥ -0.142, P ≥ 0.18) with the investigated organs was found.
Conclusions
In patients with solid tumors imaged with [\(^{68}\)Ga]Ga-PentixaFor PET/CT, no relevant tumor sink effect was noted. This observation may be of relevance for therapies with radioactive and non-radioactive CXCR4-directed drugs, as with increasing tumor burden, the dose to normal organs may remain unchanged.
Purpose
For somatostatin receptor (SSTR)-positron emission tomography/computed tomography (PET/CT), a standardized framework termed SSTR-reporting and data system (RADS) has been proposed. We aimed to elucidate the impact of a RADS-focused training on reader’s anxiety to report on SSTR-PET/CT, the motivational beliefs in learning such a system, whether it increases reader’s confidence, and its implementation in clinical routine.
Procedures
A 3-day training course focusing on SSTR-RADS was conducted. Self-report questionnaires were handed out prior to the course (Pre) and thereafter (Post). The impact of the training on the following categories was evaluated: (1) test anxiety to report on SSTR-PET/CT, (2) motivational beliefs, (3) increase in reader’s confidence, and (4) clinical implementation. To assess the effect size of the course, Cohen’s d was calculated (small, d = 0.20; large effect, d = 0.80).
Results
Of 22 participants, Pre and Post were returned by 21/22 (95.5%). In total, 14/21 (66.7%) were considered inexperienced (IR, < 1 year experience in reading SSTR-PET/CTs) and 7/21 (33.3%) as experienced readers (ER, > 1 year). Applying SSTR-RADS, a large decrease in anxiety to report on SSTR-PET/CT was noted for IR (d = − 0.74, P = 0.02), but not for ER (d = 0.11, P = 0.78). For the other three categories motivational beliefs, reader’s confidence, and clinical implementation, agreement rates were already high prior to the training and persisted throughout the course (P ≥ 0.21).
Conclusions
A framework-focused reader training can reduce anxiety to report on SSTR-PET/CTs, in particular for inexperienced readers. This may allow for a more widespread adoption of this system, e.g., in multicenter trials for better intra- and interindividual comparison of scan results.
Purpose of Review
Statins are routinely applied in patients with coronary artery disease, as they allow significantly to reduce blood cholesterol levels. Although those drugs are endorsed by current guidelines and prescribed routinely, a substantial portion of patients are still statin-intolerant and image-piloted strategies may then be helpful to identify patients that need further intensified treatment, e.g., to initiate treatment with proprotein convertase subtilisin / kexin type 9 inhibitors (PCSK9i). In addition, it has also been advocated that statins exhibit nonlipid, cardio-protective effects including improved cardiac nerve integrity, blood flow, and anti-inflammatory effects in congestive heart failure (HF) patients.
Recent Findings
In subjects after myocardial infarction treated with statins, \(^{123}\)I-metaiodobenzylguanidine (MIBG) scintigraphy has already revealed enhanced cardiac nerve function relative to patients without statins. In addition, all of those aforementioned statin-targeted pathways in HF can be visualized and monitored using dedicated cardiac radiotracers, e.g., \(^{123}\)I-MIBG or \(^{18}\)F-AF78 (for cardiac nerve function), \(^{18}\)F-flurpiridaz (to determine coronary flow) or \(^{68}\)Ga-PentixaFor (to detect inflammation).
Summary
Statins exhibit various cardio-beneficial effects, including improvement of cardiac nerve function, blood flow, and reduction of inflammation, which can all be imaged using dedicated nuclear cardiac radiotracers. This may allow for in vivo monitoring of statin-induced cardioprotection beyond lipid profiling in HF patients.